Agilent Technologies, INC.: directors' dealings · United States · SEC (Form 4)

About Agilent Technologies, INC.

Agilent Technologies, Inc. (NYSE: A) is a leading U.S. laboratory technology company listed on the New York Stock Exchange in the United States. From an international equity perspective, Agilent fits squarely within Health & Pharma, given its strong exposure to pharmaceutical, biopharmaceutical, diagnostics, academic, environmental, food, and industrial end markets. The company was incorporated in Delaware in May 1999 following the separation of Hewlett-Packard’s scientific instrumentation businesses, and it is managed from Santa Clara, California, while serving customers worldwide. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm?utm_source=openai)) Agilent’s business model centers on application-focused solutions across the laboratory workflow: instruments, software, services, and consumables. Following an organizational change announced in late 2024, the company now reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Life Sciences and Diagnostics Markets includes liquid chromatography, LC/MS-linked platforms, pathology, and companion diagnostics. Agilent CrossLab includes consumables, laboratory automation, software, informatics, and service-related offerings. Applied Markets includes gas chromatography, GC/MS, spectroscopy, remarketed instruments, and vacuum divisions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm?utm_source=openai)) Competitively, Agilent occupies a strong position in high-value analytical instrumentation, supported by a large installed base and a recurring revenue profile from consumables, service contracts, and software. Its differentiator is an integrated, workflow-oriented portfolio designed to improve laboratory productivity, compliance, and analytical throughput. That positioning places Agilent against other global instrumentation leaders, but with a meaningful specialization in analytical and clinical workflows. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm?utm_source=openai)) Key products and services include liquid and gas chromatography systems, LC/MS and GC/MS platforms, pathology solutions, companion diagnostics, laboratory consumables, and refurbishment services. Recent communications also highlight a stronger sustainability and circular-economy angle, with certified refurbishment centers, trade-in programs, and product launches aimed at improving instrument connectivity and lab productivity. ([agilent.com](https://www.agilent.com/about/newsroom/presrel/2025/27may-ca25017.html?utm_source=openai)) Geographically, Agilent has a genuinely global footprint, with operations and services across North America, Europe, and Asia-Pacific. Recent initiatives in Australia, India, Singapore, Malaysia, and South Korea underscore management’s push to deepen its presence in regional science hubs. On recent performance, the company reported first-quarter fiscal 2026 revenue of $1.80 billion, up 7.0% reported and 4.4% on a core basis, while continuing to expand its portfolio with new chromatography, pathology, and automation offerings. ([agilent.com](https://www.agilent.com/about/newsroom/presrel/2026/25feb-gp26003.html?utm_source=openai))